IgA in Biological Technology

BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease

NOVATO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and IGAN Biosciences announced today that they have initiated a program to develop an IgA protease for treating IgA nephropathy. IgA proteases have been shown to cleave IgA complexes, the depos...

BioMarin Announces First Quarter 2009 Financial Results

...velopment by the end of 2009. BMN-185 - iga protease for iga nephropathy: BioMarin is completing lead optimiza...n continuation of the program by the end of 2009. iga proteases have been shown to cleave...

Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)

...valuating the efficacy and safety of Nefecon(R) in iga nephropathy, a glomerulonephritis leading to end-s...ephropathy Patients) and at the satellite meeting, iga Nephropathy, 26-28 May in Stresa, Italy. "I...t-licensing: Nefecon(R), an effective treatment of iga nephropathy; Xepol(R), the first effective treatme...

Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development

...products to market. Pharmalink currently has three clinical phase development projects mature for out-licensing: Nefecon(R), an effective treatment of iga nephropathy; Xepol(R), the first effective treatment of neurology indication post-polio syndrome; and Busulipo(TM), a safer alternative for myeloablat...

Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

...is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective iga deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction. Immune Globulin Intravenous (...

Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease

...is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective iga deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction. Immune Globulin Intravenous (Human) p...

Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology

...is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective iga deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction. Immune Globulin Intravenous (Human) pr...

Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients

...selective IgA deficiency (IgA, 0.05 g/L) where the iga deficiency is the only abnormality of concern. About GAMMAGARD S/D with iga GAMMAGARD S/D is indicated for the treatment of ...elective IgA deficiency (IgA < 0.05 g/L) where the iga deficiency is the only abnormality of concern. Ab...